Abstract: For the production of hetero-bispecific monoclonal antibodies at least the genes for the light chain and for the variable part of the heavy chain are isolated from a hybridoma cell line which secretes an antibody with a desired specificity and they are inserted into a eukaryotic plasmid vector which contains a marker capable of selection together with a strong promoter, this expression vector is transfected into a hybridoma cell line which secretes antibodies with a second desired specificity, the cell line is cultured, the antibodies are obtained and the bispecific antibody is isolated.

Abstract: The invention involves DNA molecules which encode a human protein of 144 amino acids, referred to as interleukin-9, or IL-9. The protein is an erythropoietic growth factor. Also disclosed are processes for producing the IL-9 protein via genetic engineering techniques.

Abstract: The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.

Abstract: Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive charge provides markedly changed exotoxins. Conjugation of the new exotoxins with suitable targeting agents provides cytocidal specificity for killing desired cellular entities.

Abstract: The invention concerns murine antiidiotypic monoclonal antibodies which are the internal image of determinants recognized by a monoclonal antibody on high molecular weight-melanoma associated antigen (HMW-MAA), antibody derivatives, hybridoma cell lines secreting such antiidiotypic monoclonal antibodies, and processes for the preparation of such antiidiotypic monoclonal antibodies, of their derivatives and of the hybridoma cell lines. The murine antiidiotypic monoclonal antibodies are useful for the determination of antibodies directed against high molecular weight-melanoma associated antigen, for the modulation of the immune response to HMW-MAA and for the treatment of melanoma.

Abstract: The present invention discloses novel chimeric monoclonal antibodies directed against human carcinoembryonic antigen, having antigen-specific variable regions. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are also disclosed. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also described.

Abstract: A class of polypeptides useful in an in vitro diagnosis of Mycoplasma infection in animals is disclosed. These polypeptides are also capable of inducing an immune response in swine which were previously not exposed to Mycoplasma. Recombinant DNA methods for the production of these polypeptides and certain phage vectors and DNA sequences useful in these methods are also disclosed. Methods of vaccinating animals utilizing a vaccination composition which includes these polypeptides is also disclosed.

Abstract: A target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described. Such toxins are made by inserting specific recognition molecules at specific cloning sites in at least domain III near the carboxyl terminus of the PE molecule. Various modifications of the carboxyl terminus of the PE molecule to increase cytotoxicity are set forth. Multifunctional, recombinant, cytotoxic fusion proteins containing at least two different recognition molecules are provided for killing cells expressing receptors to which the recognition molecules bind with specificity. Methods for producing novel recombinant PE molecules with specific properties are described.

Abstract: A method for suppressing the capacity of a mammal to mount an immune response which would be caused by the administration of one or more biologically active foreign proteins, comprising the administration of an immunosuppressively effective amount of a tolerogen corresponding to the foreign protein or proteins conjugated to mono methoxy (polyethylene glycol), administration being performed prior to the administration of the protein or proteins.

Abstract: The present invention provides novel DNA sequences, recombinant DNA (rDNA) molecules, processes for producing novel T-cell proteins expressed in T-cell development, the novel T-cell proteins in substantially pure form and antibodies which bind to the novel proteins. More particularly, it relates to novel DNA sequences expressed in appropriate hosts and the novel T-cell proteins produced in these hosts. The present invention also provides novel transmembrane proteins in substantially pure form, rDNA molecules encoding transmembrane proteins and processes for producing the novel transmembrane proteins.

Abstract: Disclosed are DNA sequences which encode an amino acid sequence homologous to a segment of Trichinella spiralis 53 kilodalton excretory-secretory antigen, recombinant polynucleotide molecules containing the sequences, and transfer and replication of the sequences in a transformed host to produce antigens useful as immunodiagnostic reagents or vaccines specific for T. spiralis.

Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus.

Abstract: An in vitro method for the production of interferon is set forth. The method involves the culture of monocytes with a new DA15 peptide produced in Daudi cell lines in response to stimulation with interferon gamma.

Abstract: A unf. 13 protein and gene encoding it are disclosed which confer sensitivity to B. maydis T toxin and the insecticide methomyl, in cells carrying the gene and expressing the protein. Toxin sensitivity domains of the protein have been identified wherein a modification yields a toxin-insensitive product.

Abstract: Lymphotoxin-producing human T-cell hybridomas are incubated in a medium containing phorbol myristate acetate, concanavalin-A or a mixture thereof, the resulting cells are fractionated by sucrose density-gradient centrifugation method to isolate a messenger RNA in 12.6S to 14.6S fractions, and a gene containing a part encoding a polypeptide having a lymphotoxin-activity is prepared from the messenger RNA. The gene is represented by the nucleotide sequence of the Table 1 as herein given. Using the present gene, a new lymphotoxin having the amino acid sequence (I) or (II) as given herein can be obtained by genetic engineering technology.

Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.

Abstract: The present invention provides novel DNA sequences, recombinant DNA (rDNA) molecules, processes for producing novel T-cell proteins expressed in T-cell development, the novel T-cell proteins in substantially pure form and antibodies which bind to the novel proteins. More particularly, it relates to novel DNA sequences expressed in appropriate hosts and the novel T-cell proteins produced in these hosts. The present invention also provides novel transmembrane proteins in substantially pure form, rDNA molecules encoding transmembrane proteins and processes for producing the novel transmembrane proteins.

Abstract: A cloned gene or fragment thereof encodes antigenic proteins that bind with a monoclonal or polyvalent antibody that is directed against an antigenic protein of avian coccidia.

Abstract: This invention relates to novel recombinant antigenic proteins of avian coccidiosis, and fragments thereof containing antigenic determinants, and to the genes that encode the antigenic peptides. This invention also relates to vaccines made using the novel antigenic proteins of avian coccidiosis and to methods of immunizing chickens against avian coccidia.

Abstract: The monoclonal antibodies (mAbs) of the invention bind to a neutralizing epitope on the gp120 glycoprotein of HIV-1. The binding seems to be conformation-dependent, in the sense that altering the conformation of gp120 (by deglycosylating the gp120, by reducing the cysteine bonds in the peptide backbone) will inhibit the binding. The mAbs of the invention are group specific and can neutralize different strains and different isolates of HIV-1. The binding of these mAbs to gp120 is enhanced by the binding of other antibodies to the principal neutralizing determinant (amino acid residue numbers 296-331) of gp120.